|
Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Benzinga Array BioPharma Inc. (Nasdaq: ARRY) will report top-line results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to … |
View full post on asthma – Google News